Biocon's biosimilar of cancer drug gets European Commission approval

Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer

from Latest News https://ift.tt/2UXlmzY
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share